Analysis of the Effect of Bevacizumab as An Anti-VEGFR Pathway Drug in the Clinical Treatment of Lung Cancer

Abstract

Objective To analyze the effect of treatment with bevacizumab, an anti-VEGFR pathway drug, in patients with lung cancer. Methods 60 patients with lung cancer were used as samples, from October 2021 to February 2023, and random number table method was used to divide them into groups. Group A was treated with bevacizumab + paclitaxel protein-binding protein combined with carboplatin + cisplatin, and Group B was treated with paclitaxel protein-binding combined with carboplatin + cisplatin. Compare the differences in curative effect, tumor marker levels, immune function, toxic and side effects between the two groups. Results Lung cancer therapy in group A was higher than that in group B, P<0.05; serum tumor markers such as carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125) in group A were significantly higher than those in group B Low, P<0.05; CD4 + , CD8 + , CD4 + /CD8 + and other immune indicators in group A were better than those in group B, P<0.05; the incidence of toxic and side effects in patients with lung cancer in group A was not different from that in group B, P>0.05. Conclusion Bevacizumab, an anti-VEGFR pathway drug, is effective and feasible in the treatment of lung cancer, which can inhibit the progression of cancer, regulate the body's immune function, reduce toxic and side effects, and prolong the survival of patients.